Skip to content
Trial Eligibility
Menu

Breast Cancer Clinical Trials near Philadelphia, PA

89 studies for Breast Cancer are recruiting at 252 sites within 50 miles of Philadelphia, Pennsylvania, according to ClinicalTrials.gov data processed .

Distances are city-level approximations. See all Breast Cancer trials in the US or all trials near Philadelphia.

Your ZIP is looked up in your browser. We don't receive or store it.

Recruiting now

Breast Cancer studies enrolling near Philadelphia

Showing the 50 nearest of 89 studies.
  1. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    NCT05879926

    • Phase 3
    • Ages 18 to 60 years
    • Sex: Female

    Nearest sites: Fox Chase Cancer Center (Philadelphia, PA); Jefferson Torresdale Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    26 sites within 50 mi
  2. Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

    NCT05929768

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Jefferson Torresdale Hospital (Philadelphia, PA); Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    22 sites within 50 mi
  3. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

    NCT05812807

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Jefferson Torresdale Hospital (Philadelphia, PA); Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    14 sites within 50 mi
  4. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    NCT05564377

    • Phase 2
    • Ages Any age
    • Sex: All

    Nearest sites: Fox Chase Cancer Center (Philadelphia, PA); Pennsylvania Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    13 sites within 50 mi
  5. ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

    NCT06876714

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Jefferson Torresdale Hospital (Philadelphia, PA); Temple University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    11 sites within 50 mi
  6. De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

    NCT04852887

    • Phase 3
    • Ages 50 to 70 years
    • Sex: All

    Nearest sites: Fox Chase Cancer Center (Philadelphia, PA); Jefferson Torresdale Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    9 sites within 50 mi
  7. S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

    NCT03723928

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Thomas Jefferson University Hospital (Philadelphia, PA); Sidney Kimmel Cancer Center Washington Township (Sewell, NJ)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  8. Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

    NCT07391774

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Jefferson Torresdale Hospital (Philadelphia, PA); Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    7 sites within 50 mi
  9. A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

    NCT07174336

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Jefferson Hospital Northeast (Philadelphia, PA); Thomas Jefferson University - Clinical Research Institute (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    6 sites within 50 mi
  10. Time Restricted Eating for the Improvement of Outcomes in Patients With Stage I-III Breast Cancer Receiving Chemotherapy Before Surgery

    NCT05327608

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Jefferson Torresdale Hospital (Philadelphia, PA); Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  11. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    NCT06492616

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Fox Chase Cancer Center (Philadelphia, PA); MD Anderson Cancer Center at Cooper (Camden, NJ)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    5 sites within 50 mi
  12. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    NCT06377852

    • Phase 3
    • Ages 60 years and older
    • Sex: All

    Nearest sites: Penn Medicine - Perelman Center for Advanced Medicine (Philadelphia, PA); Penn Medicine - Chester County Hospital (West Chester, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    4 sites within 50 mi
  13. Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

    NCT05633654

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Pennsylvania Abramson Cancer Center (Philadelphia, PA); Lankenau Medical Center (Wynnewood, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  14. A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

    NCT06926868

    • Phase 2/3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Abramson Cancer Center of The University of Pennsylvania (Philadelphia, PA); Medical Oncology Hematology Consultants, PA (Newark, DE)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    3 sites within 50 mi
  15. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    NCT03452774

    • Observational
    • Ages Any age
    • Sex: All

    Nearest sites: Massive Bio SYNERGY-AI site (Philadelphia, PA); Massive Bio SYNERGY-AI site (Newark, DE)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  16. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    NCT04585750

    • Phase 1/2
    • Ages 12 years and older
    • Sex: All

    Nearest sites: Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA); Medical Oncology Hematology Consultants (Newark, DE)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  17. Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

    NCT05625659

    • Interventional
    • Ages 45 to 74 years
    • Sex: Female
    • Accepts healthy volunteers

    Nearest sites: Thomas Jefferson University Hospital (Philadelphia, PA); Thomas Jefferson University (Sewell, NJ)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  18. A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

    NCT06369285

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest sites: University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine (Philadelphia, PA); Alliance Cancer Specialists (Horsham, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  19. Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

    NCT06380751

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Research Site (Philadelphia, PA); Research Site (Camden, NJ)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  20. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    NCT06393374

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Sidney Kimmel Cancer Center at Jefferson ( Site 0049) (Philadelphia, PA); Helen F. Graham Cancer Center & Research Institute ( Site 0018) (Newark, DE)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  21. A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

    NCT06435429

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Abramson Cancer Center of The University of Pennsylvania (Philadelphia, PA); Fox Chase Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  22. QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

    NCT06551116

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA); Penn Medicine Princeton Medical Center (Plainsboro, NJ)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  23. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    NCT06778863

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Fox Chase Cancer Center (Philadelphia, PA); Thomas Jefferson University, Sidney Kimmel Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  24. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    NCT07182149

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Normunity Investigational Site (Philadelphia, PA); Normunity Investigational Site (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  25. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    NCT07213791

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Fox Chase Cancer Center (Philadelphia, PA); University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  26. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    NCT07578116

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest sites: Thomas Jefferson University Hospital (Philadelphia, PA); Asplundh Cancer Pavilion (Willow Grove, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    2 sites within 50 mi
  27. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    NCT01042379

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania (U Penn) (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  28. The Cancer of the Pancreas Screening-5 CAPS5)Study

    NCT02000089

    • Phase 3
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  29. PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

    NCT02732171

    • Interventional
    • Ages 18 years and older
    • Sex: All

    Nearest site: Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  30. The PREDICT Registry:

    NCT03448926

    • Observational
    • Ages 30 to 85 years
    • Sex: Female

    Nearest site: Sidney Kimmel Comprehensive Cancer Ctr - Jefferson (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  31. [18F] F-GLN by PET/CT in Breast Cancer

    NCT03863457

    • Phase 1
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  32. Prospective Breast Cancer Biospecimen Collection

    NCT04074720

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Sidney Kimmel Cancer Center at Thomas Jefferson University (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  33. Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

    NCT04373564

    • Phase 4
    • Ages 18 to 64 years
    • Sex: All

    Nearest site: Albert Einstein Healthcare Network (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  34. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    NCT04434040

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania-Abramson Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  35. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    NCT04468061

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania-Abramson Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  36. ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

    NCT04523857

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  37. A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

    NCT04802759

    • Phase 1/2
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  38. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    NCT04841148

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  39. ATEMPT 2.0: Adjuvant T-DM1 vs TH

    NCT04893109

    • Phase 2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania, Abramson Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  40. Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer

    NCT04959474

    • Interventional
    • Ages 40 years and older
    • Sex: All

    Nearest site: Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  41. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    NCT05059444

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  42. CTNNA1 Familial Expansion Study

    NCT05126290

    • Observational
    • Ages 18 years and older
    • Sex: All

    Nearest site: Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  43. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    NCT05232916

    • Phase 3
    • Ages 18 to 100 years
    • Sex: All

    Nearest site: Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  44. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    NCT05315700

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  45. Role of the Immune Environment in Response to Therapy in Breast Cancer

    NCT05396612

    • Observational
    • Ages 18 years and older
    • Sex: Female

    Nearest site: Abramson Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  46. ETHAN - ET for Male BC

    NCT05501704

    • Phase 2
    • Ages 18 years and older
    • Sex: Male

    Nearest site: University of Pennsylvania, Abramson Cancer Center (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  47. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    NCT05503797

    • Phase 2
    • Ages 8 years and older
    • Sex: All

    Nearest site: Thomas Jefferson University (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  48. FES BPET-DBT in Newly Diagnosed Breast Cancer

    NCT05659797

    • Early Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  49. A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    NCT05683418

    • Phase 1
    • Ages 18 years and older
    • Sex: Female

    Nearest site: University of Pennsylvania (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi
  50. Study of AVZO-021 in Patients With Advanced Solid Tumors

    NCT05867251

    • Phase 1/2
    • Ages 18 years and older
    • Sex: All

    Nearest site: Avenzo Therapeutics Recruiting Site (Philadelphia, PA)

    Distance to nearest recruiting site
    <1 mi (city-level)
    Recruiting sites
    1 site within 50 mi

FAQ

Common questions

What is a clinical trial?
A clinical trial is a research study in people that tests a medical, surgical or behavioral intervention, such as an investigational drug or device. Observational studies are also listed: they collect information without assigning a treatment. Read how clinical trials work.
Is there compensation for joining a Breast Cancer clinical trial?
Compensation for time and travel may be available, but it varies by study and some studies offer none. The amount and schedule are reviewed by an ethics board and described in the consent form. See compensation in clinical trials.
How do I check if I'm eligible?
Each study lists age, sex and other inclusion and exclusion criteria on its ClinicalTrials.gov record. Only the study team can confirm eligibility, usually through a screening call or visit. Talk with your own doctor before joining any study.

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.